Actelion Surges on Report It May Be Weighing Sale

Actelion Ltd. soared the most in more than three years after the Wall Street Journal reported that the Swiss biotechnology company may sell itself.

Actelion has formed a committee of board members to evaluate strategic alternatives, including a potential sale, the newspaper said, citing unidentified people familiar with the matter. The committee has hired a financial adviser and is likely to take up informal approaches the company has received from several large drugmakers, the Wall Street Journal said.